SCHEMBL10126288

SCHEMBL10126288

B[C@@H]1O[C@H](CO)[C@@H](O[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)[C@@H]1OC(C)=O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.37
CA1 P00915 6/20 0.35
CA2 P00918 6/20 0.35
CA4 P22748 4/20 0.35
CA5A P35218 4/20 0.35
CA5B Q9Y2D0 4/20 0.35
CA12 O43570 3/20 0.35
CA7 P43166 3/20 0.35
LGALS8 O00214 2/20 0.35
LGALS9 O00182 2/20 0.34
LGALS1 P09382 1/20 0.34
LGALS3 P17931 1/20 0.34
LGALS7; LGALS7B P47929 1/20 0.34
LMNA P02545 2/20 0.34
KMT2A Q03164 1/20 0.33
CD69 Q07108 1/20 0.32
CA9 Q16790 2/20 0.32
PTPN1 P18031 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16386068 1.00 TSHR (0.37) TSHRCA1CA2CA4CA5A
SCHEMBL10126419 0.82 TSHR (0.35) TSHRLMNAPTPN1
SCHEMBL13866335 0.80 TSHR (0.46) TSHRCA1CA2CA4CA5A
SCHEMBL14176115 0.80 TSHR (0.46) TSHRCA1CA2CA4CA5A
SCHEMBL18512832 0.79 LMNA (0.39) TSHRLMNAKMT2A
SCHEMBL707276 0.78 SLC28A1 (0.47) LMNAKMT2A
SCHEMBL17198575 0.76 TSHR (0.36) TSHRLMNAKMT2A
SCHEMBL15468488 0.75 BCHE (0.37) TSHRCA1CA2CA9
SCHEMBL13866334 0.74 TSHR (0.47) TSHRCA2LMNAKMT2A
SCHEMBL17364280 0.74 TSHR (0.47) TSHRCA2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670896-B1 CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS INC (US) 2015-01-07 EP disclosed
US-20140357856-A1 CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS, INC. (US) 2014-12-04 US disclosed
US-8791083-B2 Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry ISIS PHARMACEUTICALS, INC. (US) 2014-07-29 US disclosed
US-8124745-B2 Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation ISIS PHARMACEUTICALS, INC (US) 2012-02-28 US disclosed
US-20100216982-A1 POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION Isis Pharmaceutiacls, Inc. (US) 2010-08-26 US disclosed
US-7696345-B2 Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation ISIS PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
US-20090258931-A1 CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258931-A1 CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY NSUN3, NSUN2, NOP2 TSHR 4013/4885CA1 2532/4885CA2 3665/4885
US-20100216982-A1 POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION HNRNPC, SNRPE, IGF2BP1 TSHR 3423/4885CA1 4214/4885CA2 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.